How to Read a Biotech Clinical Trial Result: P-values, Endpoints, and Investor Implications

Clinical trials are the foundation of drug development, providing the evidence needed to determine whether a treatment is effective and safe for patients. A single clinical trial readout can add billions of dollars to a biotech company's market value or erase years of gains in a matter of hours. Yet behind headlines touting "positive data" or "statistically significant results" lies a complex set of efficacy, safety, and statistical measures that determine whether a therapy is truly a breakthrough.

Beyond terms like "met endpoint" or "statistically significant," understanding how to read clinical trial results and what trial data actually reveal about a drug's effectiveness, safety, and regulatory prospects is essential for investors, healthcare professionals, and industry observers.

Why Trial Data Literacy Matters

"Positive Phase 3 results" in a press release sounds straightforward. But what exactly was positive? Did the trial hit its primary endpoint? How large was the treatment effect? Was the result statistically significant? Did patients actually live longer, or did the drug simply delay disease progression? Was the result strong enough to change the company's commercial outlook? And how was the treatment-related adverse event profile?

Learning how to read clinical trial results is therefore one of the most important skills for biotech investors. Although advanced statistical expertise is not required, understanding the fundamental language of clinical trials is critical for interpreting study results.

The Primary Endpoint: The Most Important Number

The primary endpoint is the most important measure in a clinical trial, representing the study's main objective. It is the outcome used to determine whether the treatment achieved its intended effect and serves as the foundation for the trial's statistical design, including sample size calculations. For regulators, the primary endpoint is a critical benchmark in assessing a therapy's efficacy and supporting potential marketing approval.

A primary endpoint is the main outcome a clinical trial is designed to measure. For example, in an oncology trial, the primary endpoint might be Overall Survival (OS) or Progression-Free Survival (PFS). In a diabetes study, the expected outcome may be a reduction in HbA1c levels, while a cardiovascular trial may focus on preventing heart attacks or strokes.

Researchers select the primary endpoint before the trial begins, based on several factors: the disease being studied and its most important clinical outcomes; the drug's mechanism of action and expected benefits; regulatory guidance from agencies such as the FDA and EMA; clinical relevance, ensuring the endpoint reflects a meaningful benefit for patients; and feasibility, including the duration it will take to measure the outcome and how many patients will be needed. Once chosen, the primary endpoint is specified in the trial protocol and statistical analysis plan before any data are collected.

Statistical Significance: Understanding P-values

A p-value is a statistical measure used to assess how compatible the observed result is with a specified null hypothesis. In clinical research, the null hypothesis serves as the default assumption that a treatment has no effect. A p-value measures how compatible the study results are with the assumption that no true treatment effect exists. The lower the p-value, the less likely it is that the observed findings occurred by chance alone. Statistical significance is commonly defined at p-values below 0.05 or 0.01.

When a result is reported as p less than 0.05, it suggests the result is unlikely to have occurred by chance and is therefore considered statistically significant. For example, suppose a cancer drug improves Progression-Free Survival compared with a control treatment, and the results show p = 0.03. This means it is statistically significant, indicating that, assuming the drug has no true effect, there would be only a 3% chance of seeing a difference as large as the one observed in the trial.

A lower p-value generally provides stronger evidence that a study's findings are unlikely to be due to chance. However, p-values should not be viewed in isolation, as a very low p-value can accompany a small or clinically insignificant effect, while a result just above the conventional threshold may still be meaningful. A very large trial can detect a relatively small treatment difference with a very low p-value, while a smaller trial might produce a meaningful treatment effect but fail to reach conventional statistical significance because it lacks sufficient statistical power.

For example: Trial A showed a 1% improvement with p = 0.001, while Trial B showed a 20% improvement with p = 0.08. Trial A provides stronger statistical evidence, while Trial B may suggest a bigger potential benefit that needs to be confirmed in a larger study. This is why a clinical trial p-value should never be evaluated as a standalone metric.

Clinical Significance Versus Statistical Significance

Statistical significance indicates whether a study's results are likely due to a true treatment effect rather than random chance, typically measured using a p-value. Clinical significance, however, evaluates whether the observed effect is meaningful enough to improve patient outcomes or influence medical practice.

A statistically significant effect (p less than 0.05) only indicates that the finding is not due to chance. More detailed and extensive studies are needed to determine whether the effect is clinically significant. For example, a finding that a drug reduces blood pressure by an average of 3.5 mmHg may be statistically significant, but long-term follow-up of patients and studies of other effects of the drug are needed to assess whether this reduction is clinically significant.

Key Oncology Endpoints Explained

The success of a treatment is judged not only by tumour shrinkage but also by how long patients live and how their disease is controlled over time.

Overall Survival (OS) measures the time from a patient's diagnosis or the start of treatment to death from any cause. Widely regarded as the gold-standard endpoint in oncology, OS directly reflects the ultimate objective of cancer treatment: extending patients' lives. Because it provides a clear, objective, and clinically meaningful measure of benefit, Overall Survival is highly valued by physicians and is widely accepted by regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), when evaluating the effectiveness of new cancer therapies.

Progression-Free Survival (PFS) measures the length of time a patient remains alive without disease progression after starting treatment. The endpoint tracks the period from treatment initiation until either disease progression is observed or death occurs from any cause. PFS is an important indicator of a therapy's ability to delay disease progression and maintain disease control, making it a commonly used endpoint in oncology clinical trials.

Objective Response Rate (ORR) is the percentage of patients in a clinical trial whose cancer shrinks or disappears after treatment. ORR includes both Complete Responses (CR), in which all detectable signs of cancer disappear, and Partial Responses (PR), in which tumours shrink by a predefined amount but do not completely disappear. A higher ORR generally indicates a greater proportion of patients experienced a meaningful reduction in their cancer, although it does not necessarily show how long the response lasts or whether patients live longer as a result.

Hazard Ratios and Confidence Intervals

The Hazard Ratio (HR) is a statistical measure used to compare outcomes between two groups, such as patients receiving a new medication versus those receiving standard treatment or a placebo. HR compares the risk of an event happening in the treatment group versus the control group over time.

An HR of 1.0 means no difference between the two groups; an HR less than 1.0 means the treatment reduces the risk; and an HR greater than 1.0 indicates the treatment increases the risk.

A confidence interval (CI) is a range of values that indicates where the true treatment effect is likely to lie. While a p-value tells you whether a result is statistically significant, the confidence interval shows how precise and reliable that estimate is. For example, a Hazard Ratio of 0.75 (95% CI: 0.60–0.94) means the HR of 0.75 is the best estimate of the treatment's effect, while the 95% confidence interval (0.60–0.94) represents a margin of uncertainty around that estimate.

Secondary Endpoints: Why They Matter

Secondary endpoints are additional outcomes assessed alongside a clinical trial's primary endpoint. While they are not the primary measure of success, they provide valuable insights into a treatment's broader impact, including quality of life, duration of response, safety, symptom improvement, and biomarker changes.

Even if a trial does not meet its primary endpoint, positive secondary endpoint results may still generate useful clinical insights and inform future research, although they are typically considered supportive rather than definitive evidence of efficacy. For example, in a Phase 3 lung cancer trial where Overall Survival (OS) is the primary endpoint, secondary endpoints might include Progression-Free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DoR), Quality of Life (QoL), and safety and tolerability.

How to Quickly Evaluate a Trial Result Press Release

Clinical trial press releases are often designed to highlight positive findings, making it important to focus on the underlying data rather than the headline. A few key questions can help assess the significance of a study: Did the trial meet its primary endpoint, the study's main objective? What was the magnitude of the benefit and how much patients actually benefited? Was the result statistically significant? What do the key efficacy metrics show, and were the positive findings prespecified? How does the safety profile look?

Clinical trial readouts are often complex, but understanding the data does not have to be. Unlike FDA decisions, clinical trial results are not released on a fixed schedule; however, investors and industry observers can often anticipate key readouts by monitoring company disclosures and trial timelines.